Ola Landgren

1 month ago | jnm.snmjournals.org | Gary A. Ulaner |Jason Lewis |Ola Landgren |Molecular Imaging

Currently, the determination of disease burden in multiple myeloma is suboptimal. Myeloma cells may not secrete abnormal immunoglobulins or free light chains, limiting blood and urinary analysis (1). Imaging by radiography and MRI is limited, and approximately 30% of myeloma lesions are not appreciable by 18F-FDG PET (2). Bone marrow biopsies are also limited by the limited sites that can be sampled (3). Thus, better methods of detecting, localizing, and quantitating myeloma cells are needed.

Dec 9, 2024 | onclive.com | Ola Landgren

CommentaryVideoDecember 9, 2024Author(s):C. Ola Landgren, MD, PhD, discusses tocilizumab prophylaxis in relapsed/refractory myeloma treated with teclistamab, elranatamab, or talquetamab. C. Ola Landgren, MD, PhD, professor of medicine, chief, Division of Myeloma, Department of Medicine, University of Miami, Miller School of Medicine; director, Sylvester Myeloma Institute; co-leader, Translational and Clinical Oncology Program, Paul J.

Sep 18, 2024 | nature.com | Malin Hultcrantz |Hani Hassoun |Neha Korde |Kylee H. Maclachlan |Sham Mailankody |Urvi A. Shah | +9 more

Letter to the EditorLenalidomide is an immunomodulatory drug that is recommended and widely used as part of induction therapy and maintenance for multiple myeloma (MM) [1]. Lenalidomide maintenance is associated with significantly improved progression-free and overall survival, as shown in several clinical trials and meta-analyses [2,3,4,5,6,7]. Most patients tolerate lenalidomide well; however, fatigue and diarrhea are common side effects in the maintenance phase [3, 7, 8].

Jul 24, 2024 | onclive.com | Ola Landgren

CommentaryVideoJuly 24, 2024Author(s):C. Ola Landgren, MD, PhD, discusses standard treatment approaches and the advantages of quadruplet regimens in newly diagnosed multiple myeloma. C. Ola Landgren, MD, PhD, professor, medicine, Department of Medicine, chief, Division of Myeloma, Department of Medicine; co-leader, Translational and Clinical Oncology Program; Paul J.

Jun 4, 2024 | onclive.com | Ola Landgren

CommentaryVideoJune 4, 2024Author(s):Ola Landgren, MD, PhD, discusses the background for utilizing MRD as a clinical trial end point when evaluating multiple myeloma treatment. C. Ola Landgren, MD, PhD, professor, medicine, Department of Medicine, chief, Division of Myeloma, Department of Medicine, co-leader, Translational and Clinical Oncology Program, Paul J.